Refine by
5,197 results found
-
Hearing Voices and Turning Them Off Through Meditation
I took a leap of faith, and I had no clue how long it might take to develop the skills required to overcome this challenging symptom. -
NAMI is Building Student Resilience Throughout the School Year
As we gear up for the upcoming school year, we understand the importance of mental health for students, parents and educators. That’s why we are adding to our comprehensive youth mental health resource library this back-to-school season. -
Celebrating My Daughter’s Life and Schizophrenia Recovery
Catherine’s life wasn’t easy — and her courage, patience and eagerness to enjoy good times inspired others and still does. -
Becoming Who I was Before Schizophrenia — Or Should I?
Surviving schizophrenia, and making it to the other side, has given me a new and improved identity that I embrace. -
Hope Starts With Us: Stigma & Mental Health Equity
In this episode of NAMI’s podcast, NAMI CEO Daniel H. Gillison Jr. talks with Dr. Devika Bhushan, Dr. Napoleon Higgins and Angelina Hudson about stigma and mental health equity.
-
A Cultural Experience of Recovery
My healing process continues as I channel my past into my art and storytelling. -
FDA Approves Pill for Postpartum Depression
The U.S. Federal Drug Administration (FDA) has approved the first oral medication, Zurzuvae , for the treatment of postpartum depression (PPD). Onset of PPD can occur during the late stages of pregnancy or after childbirth. Previously, PDD medication was only available via IV injection from a health care provider. The effectiveness of Zurzuvae was tested against placebos in two distinct, randomized, double-blind studies for a period of 14 days. In both studies, patients taking Zurzuvae showed a more significant decrease in depressive symptoms at study conclusion, and four weeks after, compared to placebo groups. The approval goes a long way in improving accessibility of PPD treatment for the many individuals the condition affects each year. To learn more, read the news release from the FDA. -
Caregiving and Mental Health Stigma in My Asian American Family
Caregiving and Mental Health Stigma in My Asian American Family Trinh Dang grew up in a household that didn’t recognize mental health conditions. Yet she found herself caring for her grandmother, who had symptoms of serious mental illness. Her family faced many challenges immigrating to America. While learning to live in a new culture, they […] -
Research Finds Mixed Results in Antidepressant Maintenance Treatment of Bipolar 1
Patients with bipolar disorder experience cyclic episodes of mania and depression which makes symptom management challenging. Common treatment practices include antidepressants and mood stabilizers or antipsychotics. An international clinical trial study of 177 patients with Bipolar I in remission from a depressive episode were randomly assigned to continue antidepressant use for 52 weeks or taper antidepressant use after six weeks and begin taking a placebo at eight weeks. Patients continuing antidepressant use were significantly less likely to experience a depressive episode (17%) compared to those taking a placebo (40%). However, 12% experienced a manic episode compared to 6% in the placebo group. Further research is needed to better understand the maintenance of manic and depressive episodes in patients with bipolar disorder. To learn more, read the article in the New England Journal of Medicine. -
Acamprosate
Generic name: acamprosate (a KAM proe sate) All FDA warnings are at the end of this fact sheet. Please consult them before taking this medication. Medication Assisted Treatment (MAT) Medication assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies for the treatment of alcohol use disorder and substance use […]